

# Helene M Schoemans

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6017396/publications.pdf>

Version: 2024-02-01

59  
papers

1,935  
citations

331670

21  
h-index

276875

41  
g-index

62  
all docs

62  
docs citations

62  
times ranked

2648  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. <i>Lancet Haematology</i> , 2020, 7, e157-e167.	4.6	319
2	EBMT~NIH~CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. <i>Bone Marrow Transplantation</i> , 2018, 53, 1401-1415.	2.4	243
3	Secondary solid cancer screening following hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1013-1023.	2.4	136
4	Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). <i>Frontiers in Immunology</i> , 2020, 11, 524.	4.8	100
5	How much has allogeneic stem cell transplant~related mortality improved since the 1980s? A retrospective analysis from the EBMT. <i>Blood Advances</i> , 2020, 4, 6283-6290.	5.2	89
6	Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 535-555.	2.4	75
7	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 545-557.	1.2	72
8	Azole-resistant <i>Aspergillus fumigatus</i> due to TR46/Y121F/T289A mutation emerging in Belgium, July 2012. <i>Eurosurveillance</i> , 2012, 17, .	7.0	64
9	Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. <i>Bone Marrow Transplantation</i> , 2017, 52, 173-182.	2.4	61
10	Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. <i>Bone Marrow Transplantation</i> , 2019, 54, 44-52.	2.4	59
11	Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1493-1503.	2.0	55
12	Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 372-380.	2.4	53
13	Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 662-673.	2.4	48
14	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <i>Journal of Clinical Oncology</i> , 2020, 38, 2062-2076.	1.6	36
15	Comparative Analysis of Calcineurin Inhibitor~Based Methotrexate and Mycophenolate Mofetil~Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 73-85.	2.0	35
16	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1459-1468.	2.0	35
17	Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin~s lymphoma undergoing allogeneic haematopoietic cell transplantation~a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. <i>Bone Marrow Transplantation</i> , 2018, 53, 400-409.	2.4	34
18	miR~15a~5p and miR~21a~5p contribute to chemoresistance in cytogenetically normal acute myeloid leukaemia by targeting PDCD4, ARL2 and BTG2. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 575-585.	3.6	30

#	ARTICLE	IF	CITATIONS
19	The eGVHD App has the potential to improve the accuracy of graft-versus-host disease assessment: a multicenter randomized controlled trial. <i>Haematologica</i> , 2018, 103, 1698-1707.	3.5	24
20	Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e46-e54.	2.0	24
21	Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 953-963.	1.9	21
22	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 632-641.	1.2	21
23	Accuracy and usability of the eGVHD app in assessing the severity of graft-versus-host disease at the 2017 EBMT annual congress. <i>Bone Marrow Transplantation</i> , 2018, 53, 490-494.	2.4	19
24	Systematic Review of Patient-Reported Outcome Measures in Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e113-e127.	2.0	19
25	Development, preliminary usability and accuracy testing of the EBMT eGVHD App™ to support GvHD assessment according to NIH criteria—a proof of concept. <i>Bone Marrow Transplantation</i> , 2016, 51, 1062-1065.	2.4	18
26	Sexual Functioning in Long-Term Survivors of Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 80.e1-80.e12.	1.2	17
27	“This Graft-vs.-Host Disease Determines My Life. That’s It.” A Qualitative Analysis of the Experiences and Needs of Allogeneic Hematopoietic Stem Cells Transplantation Survivors in Germany. <i>Frontiers in Public Health</i> , 2021, 9, 687675.	2.7	17
28	Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature. <i>Acta Clinica Belgica</i> , 2021, 76, 500-508.	1.2	15
29	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 553-561.	2.0	13
30	Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 884-890.	2.4	13
31	Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS). <i>Bone Marrow Transplantation</i> , 2022, 57, 116-118.	2.4	13
32	Phenotypical diversity of airway morphology in chronic lung graft vs. host disease after stem cell transplantation. <i>Modern Pathology</i> , 2019, 32, 817-829.	5.5	12
33	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. <i>Cancer</i> , 2021, 127, 609-618.	4.1	12
34	Connective Tissue Growth Factor Is Overexpressed in Explant Lung Tissue and Broncho-Alveolar Lavage in Transplant-Related Pulmonary Fibrosis. <i>Frontiers in Immunology</i> , 2021, 12, 661761.	4.8	12
35	Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 183-190.	2.4	12
36	Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT – A Prospective, Non-interventional Study of the EBMT Transplant Complications Working Party. <i>Frontiers in Immunology</i> , 2020, 11, 586.	4.8	10

#	ARTICLE	IF	CITATIONS
37	Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 679.e1-679.e8.	1.2	10
38	A Conceptual Framework and Key Research Questions in Educational Needs of Blood and Marrow Transplantation Patients, Caregivers, and Families. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1416-1423.	2.0	9
39	Pulmonary graft-versus-host disease and chronic lung allograft dysfunction: two sides of the same coin?. <i>Lancet Respiratory Medicine</i> , 2022, 10, 796-810.	10.7	9
40	Current Practice in Vitamin D Management in Allogeneic Hematopoietic Stem Cell Transplantation: A Survey by the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2079-2085.	2.0	8
41	Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study. <i>Bone Marrow Transplantation</i> , 2021, 56, 2820-2825.	2.4	7
42	Association of uric acid levels before start of conditioning with mortality after allogeneic hematopoietic stem cell transplantation – a prospective, non-interventional study of the EBMT Transplant Complication Working Party. <i>Haematologica</i> , 2020, 105, 1977-1983.	3.5	5
43	Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research late effects and quality of life working committee. <i>Bone Marrow Transplantation</i> , 2021, 56, 786-787.	2.4	5
44	Toxoplasmosis after allogeneic haematopoietic cell transplantation: experience using a PCR-guided pre-emptive approach. <i>Clinical Microbiology and Infection</i> , 2022, 28, 440-445.	6.0	5
45	Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 335.e1-335.e17.	1.2	5
46	A case with a cytogenetically cryptic variant of the inv(16)(p13q22)/t(16;16)(p13;q22). <i>Cancer Genetics</i> , 2014, 207, 231-232.	0.4	4
47	Frequency of lethal central nervous system neurotoxicity in patients undergoing allogeneic stem cell transplantation: a retrospective registry analysis. <i>Bone Marrow Transplantation</i> , 2020, 55, 1642-1646.	2.4	4
48	How to Make an Immune System and a Foreign Host Quickly Cohabit in Peace? The Challenge of Acute Graft-Versus-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 583564.	4.8	4
49	Evaluation of the Cost of Survivorship Care After Allogeneic Hematopoietic Stem Cell Transplantation – An Analysis of 2 German Transplantation Centers. <i>Frontiers in Public Health</i> , 2020, 8, 572470.	2.7	4
50	Systematic Reviews in Hematopoietic Cell Transplantation and Cellular Therapy: Considerations and Guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and Center for International Blood and Marrow Transplant Research Late Effects and Quality of Life Working Committee. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 380-388.	1.2	4
51	Management of growth failure and growth hormone deficiency after pediatric allogeneic HSCT: Endocrinologists are of importance for further guidelines and studies. <i>Pediatric Hematology and Oncology</i> , 2019, 36, 494-503.	0.8	3
52	Bone healing with bortezomib-based regimens in multiple myeloma: a retrospective imaging study. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 387-394.	1.6	2
53	Pre-Transplant Marital Status and Hematopoietic Cell Transplantation Outcomes. <i>Current Oncology</i> , 2020, 27, 596-606.	2.2	2
54	Influence of pretransplant inflammatory bowel disease on the outcome of allogeneic hematopoietic stem cell transplantation: a matched-pair analysis study from the Transplant Complications Working Party (TCWP) of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 3084-3087.	2.4	2

#	ARTICLE	IF	CITATIONS
55	Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 1150-1163.	2.4	2
56	eHealth generated patient data in an outpatient setting after stem cell transplantation: a scoping review. <i>Transplantation and Cellular Therapy</i> , 2022, , .	1.2	2
57	Practice patterns in chronic graft-versus-host disease patient management and patient reported outcome measures across the EBMT allogeneic transplantation network. <i>Bone Marrow Transplantation</i> , 2022, 57, 1458-1460.	2.4	2
58	One step at a time. <i>Blood</i> , 2021, 138, 1208-1209.	1.4	0
59	Prevalence of and Factors Associated with Marital Distress among Hematopoietic Cell Transplantation Survivors: Results from a Large Cross-Sectional Study. <i>Transplantation and Cellular Therapy</i> , 2022, , .	1.2	0